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ABSTRACT
Cell-free (cf) DNA in the plasma of cancer patients offers an easily obtainable 
source of biologic material for mutation analysis. Plasma samples from 157 patients 
with advanced cancers who progressed on systemic therapy were tested for 21 
mutations in BRAF, EGFR, KRAS, and PIK3CA using the BEAMing method and 
results were compared to mutation analysis of archival tumor tissue from a CLIA-
certified laboratory obtained as standard of care from diagnostic or therapeutic 
procedures.Results were concordant for archival tissue and plasma cfDNA in 91% 
cases for BRAF mutations (kappa = 0.75, 95% confidence interval [CI] 0.63 – 
0.88), in 99% cases for EGFR mutations (kappa = 0.90, 95% CI 0.71– 1.00), 
in 83% cases for KRAS mutations (kappa = 0.67, 95% CI 0.54 – 0.80) and in 
91% cases for PIK3CA mutations (kappa = 0.65, 95% CI 0.46 – 0.85). Patients 
(n = 41) with > 1% of KRAS mutant cfDNA had a shorter median survival compared 
to 20 patients with </= 1% of KRAS mutant DNA (4.8 vs. 7.3 months, p = 0.008). 
Similarly, 67 patients with > 1% of mutant cfDNA (BRAF, EGFR, KRAS, or PIK3CA) 
had a shorter median survival compared to 33 patients with </= 1% of mutant cfDNA 
(5.5 vs. 9.8 months, p = 0.001), which was confirmed in multivariable analysis.
INTRODUCTION
The discovery of oncogenic mutations has 
expanded our understanding of the mechanisms of 
tumorigenesis and led to the development of targeted 
cancer therapies directed at specific druggable targets. 
[1–5] Examples include BRAF inhibitors in melanoma 
harboring BRAF mutations, ABL kinase inhibitors 
in chronic myelogenous leukemia with BCR-ABL 
fusion, EGFR tyrosine kinase inhibitors in non-small 
cell lung cancer (NSCLC) with an EGFR mutation, 
and others. [1–10] Currently, oncogenic mutations are 
tested using archival formalin-fixed, paraffin-embedded 
tumor tissue (FFPE) and its lack of availability is 
often a limiting factor, precluding mutation analysis. 
In addition, mutation analysis of primary tumor tissue 
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or of an isolated metastasis does not, due to tumor 
heterogeneity, necessarily reflect the genetic make-up 
of metastatic disease. [11–15] It has been reported that 
distinct oncogenic mutations occur in different areas 
of a primary tumor and that there is a discrepancy in 
approximately 20–30% of cases between the mutation 
status in primary tumor versus distant metastases. [11, 
12] In addition, translational studies in EGFR-mutated 
NSCLC suggested that the cancer genotype can change 
over time. [13] Sequist et al. demonstrated, in a group 
of 37 patients with EGFR-mutant NSCLC who had 
pre-treatment and post-progression tumor biopsies, 
that some mutations occur and disappear over time. 
[13] For example, patients who initially responded to 
an EGFR tyrosine kinase inhibitor developed an EGFR 
T790M mutation or PIK3CA mutation at the time of 
disease progression. Consequently, their treatment 
regimens were changed and the EGFR T790M and 
PIK3CA mutations were no longer detectable in the 
tumor samples collected a couple of months later, and 
patients responded again to retreatment with an EGFR 
tyrosine kinase inhibitor. [13] Having a technique 
available to elucidate molecular changes potentially 
underlying drug resistance is of special importance as 
most patients treated with matched targeted therapies, 
despite improved response rates and longer progression-
free survival, ultimately develop therapeutic resistance 
and disease progression.
Cell-free (cf) DNA is released to the circulation 
from cells undergoing apoptosis or necroptosis in 
primary or metastatic cancer lesions or in the tumor 
microenvironment and can be identified in the blood 
samples of patients with cancer. [16] Unlike performing 
tissue biopsies, obtaining samples of plasma cfDNA is a 
noninvasive approach, with less risk to patients at a lower 
cost. Therefore, in patients with advanced cancer, we 
investigated whether mutation analysis of plasma-derived 
cfDNA has an acceptable level of concordance with 
routine clinical mutation analysis for common oncogenic 
mutations in BRAF, EGFR, KRAS, and PIK3CA. Tissue 
testing obtained from prior surgeries and biopsies was 
performed in the Clinical Laboratory Improvement 
Amendment (CLIA)–certified Molecular Diagnostic 
Laboratory at The University of Texas MD Anderson 
Cancer Center (MD Anderson).
RESULTS
Patients
A total of 157 patients with diverse advanced 
cancers with known FFPE tumor tissue mutation status for 
mutations in at least one of the selected cancer genes, which 
included BRAF, EGFR, KRAS, PIK3CA, were enrolled 
(Table 1). Their median age was 58 years (range, 20 to 84 
years) and most patients (n = 118, 75%) were white and 
men (n = 81, 52%). The most common tumor types were 
colorectal cancer (n = 68, 43%), melanoma (n = 34, 22%), 
NSCLC (n = 13, 8%), appendiceal cancer (n = 5, 3%), 
ovarian cancer (n = 5, 3%) and uterine cancer (n = 5, 3%) 
(Table 2). The median time between FFPE tumor tissue 
and plasma collection was 16.5 months (range, 0–144. 
7 months). Table 3 provides information about experimental 
therapies that were given.
Mutations and discrepancy analysis
Of the 157 patients, 137 were tested for BRAF 
mutation in tumor and cfDNA samples; 38 (28%) patients 
had a BRAF V600 mutation in the FFPE tumor samples 
and 33 (24%) had BRAF V600 mutations in cfDNA from 
plasma, with overall agreement between testing modalities 
in 124 (91%) cases (kappa 0.75, SE 0.07, 95% confidence 
interval [CI] 0.63–0.88) with sensitivity 76% (95% CI 
0.60–0.89), specificity 96% (95% CI 0.90–0.99), positive 
predictive value 88% (95% CI 0.72–0.97) and negative 
predictive value 91% (95% CI 0.84–0.96; Table 1). Of 
9 patients (melanoma, n = 6; colorectal, n = 1; papillary 
thyroid, n = 1; appendiceal cancer, n = 1) with BRAF 
V600E mutation in the tumor tissue but not in cfDNA, one 
patient (papillary thyroid cancer) had wtBRAF when the 
tumor tissue (we used the same block as used for initial 
tissue testing, if possible) was tested with BEAMing. Three 
patients (all melanoma) had plasma collection immediately 
after coming off BRAF or MEK targeted therapy and 1 
patient (appendiceal cancer) had plasma collection right 
after being taken off standard chemotherapy without 
evidence of disease progression. Of interest, the latter 
patient had another cfDNA analysis for a BRAF mutation 
when her disease progressed and at that time BRAF V600E-
mutant cfDNA was detected. In addition, a patient with 
colorectal cancer and a BRAF V600E mutation in the tumor 
tissue, but not in cfDNA, was found to have a KRAS G12D 
mutation in cfDNA, which was not detected in the tumor 
tissue. Furthermore, we found a BRAF V600K mutation in 
cfDNA in 4 patients with wt BRAF in their tumor tissue. 
Of interest, 2 of these 4 patients (colorectal cancer and 
NSCLC) also had KRAS G12 mutations in FFPE tumor 
samples and cfDNA. Finally, a patient with melanoma had 
a BRAF V600E mutation in the tissue, but a BRAF V600K 
mutation in cfDNA; however, repeated testing of tumor 
tissue with BEAMing confirmed a BRAF V600K mutation. 
We also analyzed whether the amount of BRAF-mutant 
cfDNA correlated with discrepancies between cfDNA and 
tumor tissue and, indeed, patients with concordant results 
between cfDNA and tissue had a median of 1.99% of 
BRAF-mutant cfDNA compared to a median of 0.02% of 
BRAF-mutant cfDNA in patients with discrepant results 
(p = 0.001).
Of the 157 patients, 79 were tested for EGFR in 
tumor and cfDNA samples; 5 (6%) patients had EGFR 
mutations in the FFPE tumor samples and 6 (8%) had 
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EGFR mutations in cfDNA from plasma, with overall 
agreement between testing in 78 (99%) cases (kappa = 1.00, 
SE 0.10, 95% CI 0.71–1.00) with sensitivity 100% (95% 
CI 0.48–1.00), specificity 99% (95% CI 0.93–1.00), 
positive predictive value 83% (95% CI 0.36–0.97) and 
negative predictive value 100% (95% CI 0.95–1.00; 
Table 1). A patient with Erdheim-Chester disease had an 
EGFR T790M mutation not previously identified in FFPE 
tumor samples. Furthermore, 2 patients with EGFR-mutant 
NSCLC previously treated with EGFR tyrosine kinase 
inhibitors also had a second EGFR T790M mutation not 
previously identified in the FFPE tumor samples, which 
can plausibly explain why secondary resistance to EGFR 
targeted therapies occurred. Of interest, a patient treated 
with erlotinib, who had a biopsy at the time of disease 
progression revealing an EGFR exon 19 deletion and 
EGFR T790M mutation, demonstrated no EGFR T790M 
mutation in cfDNA after 10 months of being taken off of 
Table 1: Mutations tested in cfDNA and concordance between tumor tissue and cfDNA
Mutations tested
Gene Exon Mutation type
BRAF 15 V600E
V600K
EGFR 19 Δ E746_A750 (2235_2249del15)
Δ E746_A750 (2235_2250del15)
Δ E746_S752 ins V
Δ L747_A750 ins P
Δ L747_T751
Δ L747_P753 ins S
20 T790M
21 L858R
KRAS 2 G12S
G12R
G12C
G12D
G12A
G12V
G13D
PIK3CA 9 E542K
E545K
20 H1047R
H1047L
Concordance between mutation testing of tumor tissue and cfDNA
TESTED (N = 137) BRAF mutation in tumor BRAF wild-type in tumor
BRAF mutation in cfDNA 29 4
BRAF wild-type in cfDNA 9 95
Observed agreements 124 (91%); Kappa 0.75, SE 0.06; 95 CI% 0.63–0.88
Sensitivity 76% (95% CI 0.60–0.89)
Specificity 96% (95% CI 0.90–0.99)
Positive predictive value 88% (95% CI 0.72–0.97)
Negative predictive value 91% (95% CI 0.84–0.96)
(Continued )
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TESTED (N = 79) EGFR mutation in tumor EGFR wild-type in tumor
EGFR mutation in cfDNA 5 1
EGFR wild-type in cfDNA 0 73
Observed agreements 78 (99%); Kappa 0.90, SE 0.10; 95 CI% 0.71–1.00
Sensitivity 100% (95% CI 0.48–1.00)
Specificity 99% (95% CI 0.93–1.00)
Positive predictive value 83% (95% CI 0.36–0.97)
Negative predictive value 100% (95% CI 0.95–1.00)
TESTED (N = 121) KRAS mutation in tumor KRAS wild-type in tumor
KRAS mutation in cfDNA 49 8
KRAS wild-type in cfDNA 12 52
Observed agreements 101 (83%); Kappa 0.67, SE 0.07; 95 CI% 0.54–0.80
Sensitivity 80% (95% CI 0.68–0.89)
Specificity 87% (95% CI 0.75–0.94)
Positive predictive value 86% (95% CI 0.74–0.94)
Negative predictive value 81% (95% CI 0.70–0.90)
TESTED (N = 107) PIK3CA mutation in tumor PIK3CA wild-type in tumor
PIK3CA mutation in cfDNA 12 8
PIK3CA wild-type in cfDNA 2 85
Observed agreements 97 (91%); Kappa 0.65, SE 0.10; 95 CI% 0.46–0.85
Sensitivity 86% (95% CI 0.57–0.98)
Specificity 91% (95% CI 0.84–0.96)
Positive predictive value 60% (95% CI 0.36–0.81)
Negative predictive value 98% (95% CI 0.92–1.00)
Table 2: Clinical characteristics of 157 patients with advanced cancers
Parameter Value
Age
 Median age (range) 58 (20–84)
Gender
 Men (%) 81 (52)
 Women (%) 76 (48)
Ethnicity
 White (%) 118 (75)
 African-American (%) 20 (13)
 Hispanic (%) 15 (10)
 Asian (%) 4 (3)
Tumor type
 Colorectal cancer (%) 68 (43)
 Melanoma (%) 34 (22)
(Continued )
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erlotinib therapy. Because of the low number of patients 
with EGFR mutations, we did not perform analysis to test 
associations between the amount of mutant cfDNA and the 
rate of discrepancies (tumor tissue vs. cfDNA).
Of the 157 patients, 121 were tested for KRAS in 
tumor and cfDNA samples; 61 (50%) patients had KRAS 
G12 or 13 mutations in the FFPE tumor samples and 
57 (47%) had KRAS mutations in cfDNA from plasma 
with overall agreement between testing in 101 (83%) 
cases (kappa = 0.67, SE 0.07, 95% CI 0.54–0.80) with 
sensitivity 80% (95% CI 0.68–0.89), specificity 87% 
(95% CI 0.75–0.94), positive predictive value 86% (95% 
CI 0.74–0.94) and negative predictive value 81% (95% 
CI 0.70–0.90; Table 1). Of 12 patients (colorectal, n = 6; 
Parameter Value
 Non-small cell lung cancer (%) 13 (8)
 Ovarian cancer (%) 5 (3)
 Appendiceal cancer (%) 5 (3)
 Uterine cancer (%) 5 (3)
 Breast cancer (%) 4 (3)
 Non-squamous head and neck cancer (%) 4 (3)
 Gastroesophageal cancer (%) 3 (2)
 Papillary thyroid cancer (%) 3 (2)
 Prostate cancer (%) 2 (2)
 Soft tissue sarcoma (%) 2 (2)
 Ampullary cancer (%) 1 (<1)
 Cholangiocarcinoma (%) 1 (<1)
 Merkel cell cancer (%) 1 (<1)
 Small cell lung cancer (%) 1 (<1)
 Carcinoma of unknown primary (%) 1 (<1)
 Duodenal cancer (%) 1 (<1)
 Hepatocellular carcinoma (%) 1 (<1)
 Squamous head and neck cancer (%) 1 (<1)
 Erdheim-Chester disease (%) 1 (<1)
Table 3: Experimental therapies in patients with BRAF, EGFR, KRAS and PIK3CA mutations
Mutation Total Matched therapy Non-matched therapy No therapy
BRAF (tumor) 38 331 2 3
BRAF (cfDNA) 33 291 1 3
EGFR (tumor) 5 42 1 0
EGFR (cfDNA) 6 42 2 0
KRAS (tumor) 61 03 47 14
KRAS (cfDNA) 57 03 43 14
PIK3CA (tumor) 14 94 4 1
PIK3CA (cfDNA) 20 84 9 3
1BRAF and MEK inhibitors were considered as matched therapies
2EGFR inhibitors were considered as matched therapies
3There were no matched therapies
4PI3K/AKT/mTOR inhibitors were considered as matched therapies
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appendiceal cancer, n = 2; NSCLC, n = 2; duodenal, n = 1; 
breast cancer, n = 1) who had KRAS G12 or G13 mutations 
in the tumor tissue did not have these mutations in their 
cfDNA. In addition, of 8 patients (colorectal cancer, 
n = 3; NSCLC, n = 1; endometrial cancer, n = 1; breast 
cancer, n = 1; ovarian cancer, n = 1; melanoma, n = 1) 
with KRAS G12 or G13 mutation in cfDNA, but not in 
FFPE tumor samples, 2 patients had KRAS Q61 mutations 
in FFPE. We also analyzed whether the amount of 
KRAS-mutant cfDNA correlated with discrepancies 
between cfDNA and tissue. Patients with concordant 
results between cfDNA and tissue had a median of 7.46% 
 KRAS-mutant cfDNA compared to a median of 0.55% 
KRAS-mutant cfDNA in patients with discrepant results 
(p = 0.048).
Of the 157 patients, 107 were tested for PIK3CA in 
tumor and cfDNA samples; in 14 (13%) patients PIK3CA 
mutations were detected in FFPE tumor samples and 20 
(19%) had PIK3CA mutations in cfDNA from plasma 
with overall agreement between testing in 97 (91%) 
cases (kappa = 0.65, SE 0.10, 95% CI 0.46–0.85) with 
sensitivity 86% (95% CI 0.57–0.98), specificity 91% 
(95% CI 0.84–0.96), positive predictive value 60% (95% 
CI 0.36–0.81) and negative predictive value 98% (95% 
CI 0.92–1.00; Table 1). Two patients (breast cancer, 
n = 1; NSCLC, n = 1) had a PIK3CA H1047R mutation 
their FFPE tumor samples, but not in cfDNA. In contrast, 
8 patients (colorectal cancer, n = 4; squamous cell head 
and neck, n = 1; non-squamous head and neck cancer, 
n = 1; breast, n = 1; NSCLC, n = 1) had PIK3CA E542K 
or E545K mutations in cfDNA but not in FFPE tumor 
samples. Of interest, 3 of these patients (head and neck, 
n = 2; NSCLC, n = 1) were also known to have EGFR 
mutations and progressed on an EGFR monoclonal 
antibody or tyrosine kinase inhibitor, suggesting that a 
PIK3CA mutation could have been a driver of therapeutic 
resistance. In addition, 2 patients (both with colorectal 
cancer) had a different PIK3CA mutation in the FFPE 
tumor samples (Q546P and E545D/M1043L, which were 
not included in the BEAMing panel). Finally, 4 patients 
with PIK3CA mutations in cfDNA, but not FFPE tumor 
samples, had simultaneous KRAS mutations in cfDNA 
and FFPE tumor samples. We also analyzed whether 
the amount of PIK3CA-mutant cfDNA correlated with 
discrepancies between cfDNA and tumor tissue and 
patients with concordant results in cfDNA and tumor 
tissue had a median of 1.83% of PIK3CA-mutant cfDNA 
compared to a median of 2.61% of PIK3CA-mutant 
cfDNA in patients with discrepant results (p = 0.50).
Emergence of low frequency mutations in cfDNA
In several patients, testing of cfDNA revealed 
mutations not previously detected in the tumor tissue, 
which in some of them could have plausibly explained 
resistance to pertinent targeted therapies. For instance, a 
patient with NSCLC with wt BRAF and a KRAS G12C 
mutation in the tissue and cfDNA (3.80%) was also found 
to have a low frequency BRAF V600K mutation in cfDNA 
(0.03) at the time of disease progression while taking a 
MEK inhibitor for 3.7 months. A patient with colorectal 
cancer with wt BRAF and wt KRAS in the primary tumor, 
who received a cetuximab-based combination for nearly 
one year had an emergence of a low frequency BRAF 
V600K mutation in cfDNA (0.02%).
Furthermore, a patient with NSCLC and an EGFR 
L858R mutation found in an original tumor biopsy had 
cfDNA collection after developing secondary resistance to the 
EGFR tyrosine kinase inhibitor erlotinib, which in addition to 
a known EGFR L858R mutation (0.11%), revealed an EGFR 
T790M mutation (0.04%), plausibly explaining secondary 
resistance to erlotinib. A patient with NSCLC and an EGFR 
exon 19 deletion from the original biopsy had cfDNA 
collected after becoming refractory to erlotinib; cfDNA 
revealed, in addition to an EGFR exon 19 deletion (6.42%), 
EGFR T790M (0.65%) and PIK3CA E545K (0.67%) 
mutations not previously identified in the earlier tissue testing, 
which can credibly explain the emergence of resistance. A 
patient with NSCLC and an EGFR exon 19 deletion was 
also found to have a simultaneous EGFR T790M mutation 
on a tumor biopsy obtained after progression while taking 
the EGFR tyrosine kinase inhibitor erlotinib; however, unlike 
with the EGFR exon 19 deletion (12.86%),  EGFR T790M 
was no longer present in cfDNA obtained 10 months after 
having been taken off erlotinib.
Furthermore, a patient with a BRAF V600E-
mutant, wt KRAS colorectal cancer, with a history of early 
progression to cetuximab-based therapy, was found to have 
a KRAS G12D mutation (24.39%) in cfDNA instead, which 
was not previously detected in the tumor tissue. A patient 
with wt KRAS in the initial tumor tissue biopsy who had a 
transient response (4 months) to cetuximab-based therapy 
was then found to have a KRAS G13D mutation (0.88%) in 
cfDNA. Finally, a patient with ovarian cancer and a PIK3CA 
H1047R mutation in an original FFPE tumor sample, who 
had dramatic but short-lived response to an investigational 
agent targeting PI3K alpha, was found, in addition to having 
a PIK3CA H1047R mutation (0.08%), a low frequency 
KRAS G12C mutation (0.03%) in cfDNA from plasma 
collected before initiation of a PI3K inhibitor, which can 
reasonably explain early therapeutic failure. [21, 22]
Further, a patient with mucoepidermoid carcinoma of 
the nasal-lacrimal sac with wt PIK3CA and an EGFR exon 18 
mutation (A722V) on an initial biopsy was also found to have 
a PIK3CA E545K mutation in cfDNA, and the patient was 
ultimately refractory to treatment with the EGFR tyrosine 
kinase inhibitor erlotinib. Also, a patient with squamous cell 
carcinoma of head and neck with wt PIK3CA and an EGFR 
exon 21 mutation (H835L) in an initial resected tumor was 
found to have a PIK3CA E545K mutation (0.05%) in cfDNA 
collected after progressive disease following 3 months of 
cetuximab, carboplatin and paclitaxel treatment.
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Mutations in cfDNA and overall survival
Next we investigated whether the amount of mutant 
cfDNA (percentage compared to wt) had any impact 
on overall survival (OS). Our strategy was to compare 
patients with </= 1% of mutant cfDNA vs. > 1% cfDNA 
to make comparable categories. These thresholds were 
selected based on a 5% trimmed mean value of mutated 
cfDNA for all tested genes, which was deemed to be more 
representative since it was not affected by the number 
of patients without cfDNA mutations. In addition, these 
thresholds reflect approximate medians of the percent of 
mutant DNA for BRAF, EGFR, KRAS and PIK3CA (1%, 
2.7%, 3.8% and 0.5%, respectively).
In 33 patients with BRAF mutations in cfDNA, 
16 patients with </= 1% of BRAF-mutant cfDNA had 
survival rates similar to 17 patients with > 1% of BRAF-
mutant cfDNA (8.9 months, 95% CI 7.3–10.5 vs. 7.3 
months, 95% CI 4.5–10.1; p = 0.38; Figure 1A). Of 
interest, 20 patients with </= 1% of KRAS-mutant cfDNA 
had a longer median survival compared to 41 patients 
with > 1% of KRAS-mutant cfDNA (7.3 months, 95% 
CI 5.3–9.3 vs. 4.8 months, 95% CI 3.8–5.8; p = 0.008; 
Figure 1B). Finally, 14 patients with </= 1% of PIK3CA-
mutant cfDNA had a similar length of survival as did 
13 patients with > 1% of PIK3CA-mutant cfDNA (8.0 
months, 95% CI 4.0–12.0 vs. 5.6 months, 95% CI 4.7–6.5; 
p = 0.15; Figure 1C). Survival analysis for patients with 
EGFR mutations has not been performed due to the low 
number of patients in that group.
Next, we performed an analysis combining all tested 
mutations (BRAF, EGFR, KRAS, PIK3CA) in all of 105 
patients with mutant cfDNA. When there was more than 
one mutation in the same patient, the mutation with the 
highest percentage of mutant DNA was used for analysis. 
Patients (n = 38) with </= 1% of mutant cfDNA had longer 
Figure 1: (A) In 33 patients with BRAF mutations in cfDNA, 16 patients with </= 1% (blue) of BRAF mutations had survival similar 
to 17 patients with > 1% (red) of BRAF mutations (8.9 months, 95% CI 7.3–10.5 vs. 7.3 months, 95% CI 4.5–10.1; p = 0.38). (B) In 
61 patients with KRAS mutations in cfDNA, 20 patients with </= 1% (blue) of KRAS mutations had longer median survival compared to 
41 patients with > 1% (red) of KRAS mutations (7.3 months, 95% CI 5.3–9.3 vs. 4.8 months, 95% CI 3.8–5.8; p = 0.008). (C) In 27 patients 
with PIK3CA mutations in cfDNA, 14 patients with </= 1% (blue) of PIK3CA mutations had survival similar to 13 patients with > 1% 
(red) of PIK3CA mutations (8.0 months, 95% CI 4.0–12.0 vs. 5.6 months, 95% CI 4.7–6.5; p = 0.15). (D) In 105 patients with BRAF, 
EGFR, KRAS, or PIK3CA mutations in cfDNA, 38 patients with </= 1% (blue) of mutant cfDNA had longer median survival compared to 
67 patients with > 1% (red) of mutant cfDNA (9.8 months, 95% CI 7.5–12.1 vs. 5.5 months, 95% CI 5.0–6.0; p = 0.001).
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median survivals compared to 67 patients with > 1% of 
mutant cfDNA (9.8 months, 95% CI 7.5–12.1 vs. 5.5 
months, 95% CI 5.0–6.0; p = 0.001; Figure 1D).
Finally, we analyzed the prognostic impact of cfDNA 
mutations on OS in multivariable analysis, which included 
the Royal Marsden Hospital prognostic score (RMH 
score) and the MD Anderson (MDACC) score. [23, 24] 
The RMH score is a prospectively validated tool used to 
predict OS in patients with advanced cancers referred for 
early-phase clinical trials. It is calculated on the basis of 
lactate dehydrogenase levels (> upper limit of normal vs. 
normal), albumin levels (<3.5 g/mL vs. 3.5 g/mL or higher) 
and number of metastatic sites (> 2 sites vs. 2 sites or less) 
and scores of 0–1 are associated with better survival than 
scores of 2–3. Similarly, the MDACC prognostic score 
included the factors listed above for the RMH score as 
well as ECOG performance status (0 vs. >/=1) and type of 
tumor (gastrointestinal vs. other).
In 61 patients with KRAS mutations in cfDNA, 
31 patients with RMH scores of 0–1 had longer median 
survivals than 30 patients with RMH scores of 2–3 (5.7 
months, 95% CI 4.4–7.0 vs. 4.8 months, 95% CI 3.9–5.7; p = 
0.036, Figure 2A). In multivariable analysis, which included 
KRAS mutations in cfDNA (</= 1% vs. > 1%) and the RMH 
score (0–1 vs. 2–3), patients with KRAS mutations in </= 1% 
of cfDNA had a trend toward a longer survival compared to 
patients with KRAS mutations in > 1% of cfDNA (hazard 
ratio [HR] 0.53, 95% CI 0.27–1.03, p = 0.06).
In a combined analysis of 105 patients with cfDNA 
mutations, 57 patients with RMH scores of 0–1 had longer 
median survivals than 48 patients with RMH scores of 
2–3 (7.4 months, 95% CI 4.9–9.9 vs. 5.3 months, 95% CI 
4.2–6.4; p = 0.029, Figure 2B). Similarly, 41 patients with 
MDACC scores of 0–2 had longer median survivals than 
64 patients with MDACC scores of 3–5 (7.4 months, 95% 
CI 4.5–10.3 vs. 5.3 months, 95% CI 4.3–6.3; p = 0.002; 
Figure 2C). In multivariable analysis, which included 
mutant cfDNA (</= 1% vs. > 1%) and RMH score (0–1 
vs. 2–3), patients with </= 1% of mutant cfDNA had a 
longer survival compared to patients with > 1% of mutant 
Figure 2: (A) In 61 patients with KRAS mutations in cfDNA, 31 patients with scores of 0–1 had longer median survival than 30 patients 
with RMH scores of 2–3 (5.7 months, 95% CI 4.4–7.0 vs. 4.8 months, 95% CI 3.9–5.7; p = 0.036). (B) In a combined analysis of 
105 patients with any cfDNA mutation, 57 patients with RMH scores of 0–1 had longer median survival than did 48 patients with RMH 
scores of 2–3 (7.4 months, 95% CI 4.9–9.9 vs. 5.3 months, 95% CI 4.2–6.4; p = 0.029). (C) In a combined analysis of 105 patients with 
any cfDNA mutation, 41 patients with MDACC scores of 0–2 had longer median survival than 64 patients with MDACC scores of 3–5 
(7.4 months, 95% CI 4.5–10.3 vs. 5.3 months, 95% CI 4.3–6.3; p = 0.002).
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cfDNA (HR 0.49, 95% CI 0.29–0.81, p = 0.005). Similar 
results were obtained using the MDACC score (HR 0.51, 
95% CI 0.32–0.82, p = 0.005, Table 4).
DISCUSSION
In our study, we demonstrated that using the 
BEAMing technology, testing for 21 oncogenic mutations 
in BRAF, EGFR, KRAS and PIK3CA genes in the plasma 
cfDNA of patients with advanced cancers referred for 
treatment with experimental targeted therapies, is feasible. 
In addition, testing of cfDNA demonstrated acceptable 
concordance (BRAF, 91%; EGFR, 99%; KRAS, 83%; 
PIK3CA, 91%) with standard of care mutation analysis 
of primary or metastatic tumor tissue obtained during 
clinical care. Higgins et al. [17] demonstrated a 100% 
concordance between using BEAMing to assess PIK3CA 
mutations in plasma cfDNA versus using BEAMing for 
PIK3CA mutations in the tumor tissue in a cohort of 
patients with advanced breast cancer when the plasma and 
tumor samples were obtained at the same time. However, 
the concordance decreased to 79% when tumor samples 
and plasma cfDNA were obtained at different time points. 
Board et al. [24] demonstrated a 95% concordance 
between PIK3CA mutation status in plasma cfDNA 
and tumor tissue obtained at the same time by using an 
amplification refractory mutation system. Most recently, 
Thierry et al. [25] demonstrated a 96% concordance for 
combined KRAS and BRAF mutation testing using allele-
specific quantitative PCR of plasma cfDNA compared to 
tissue (primary or metastatic) tested as standard of care. It 
is conceivable that mutation analysis results from cfDNA 
are highly concordant with mutation analysis results from 
tumor tissue if both materials are obtained concomitantly. 
However, the concordance rate can decrease, perhaps due 
to inherent heterogeneity, if both materials are obtained at 
different time points. This is not unexpected, since similar 
observations were made in a study in 33 matched primary 
and recurrent breast tumors, in which 97 of 112 (86.6%) 
somatic mutations were concordant. [26] It is unclear, 
why our results demonstrated the lowest concordance 
for KRAS compared to other genes (83% vs 91%–99%) 
and whether this was related to underlying biology or 
technology (or both).
Detection of molecular aberrations in cfDNA can be 
also used to monitor response to therapy and emergence of 
secondary mutations associated with resistance to therapy, 
which can plausibly be used for therapeutic interventions. 
[27, 28] Because plasma cfDNA can originate from 
multiple tumor sites, arguably its molecular analysis 
may better reflect prevailing molecular aberrations 
than obtained from single-site biopsied tissue. [29, 30] 
In addition, unlike tissue biopsies, obtaining samples 
of cfDNA is a noninvasive approach, with less risk to 
patients at a lower cost. Diehl et al. [16], in a pilot study 
of 18 patients with metastatic colorectal cancer who were 
indicated as being candidates for surgical resection or 
radiofrequency ablation, showed that cfDNA from plasma 
samples can be isolated and oncogenic mutations (APC, 
KRAS, TP53) can be detected in all tested patients using 
the BEAMing PCR-based technology. Further, analysis 
of a quantity of mutant copies more accurately predicted 
disease progression than standard evaluation of serum 
CEA levels. In a study of patients with metastatic breast 
cancer, 97% had genetic alterations in cfDNA and changes 
in cfDNA mutation levels correlated with changes in 
tumor burden to a greater degree than indicated by a CA 
15–3 prognostic marker. Furthermore, two pilot studies 
in advanced colorectal cancer patients with wtKRAS 
demonstrated emerging KRAS aberrations in cfDNA 
during treatment with an anti-EGFR therapy [31, 32]. The 
first study published reported that 38% of patients treated 
with the anti-EGFR monoclonal antibody cetuximab, 
who were known to have wt KRAS on the basis of tumor 
tissue analysis, later developed KRAS mutations. These 
mutations were detectable in blood samples, usually 
between 5 and 6 months following treatment. [31] The 
second study, in patients who developed resistance to 
cetuximab or panitumumab, showed the emergence of 
KRAS amplification in one sample and acquisition of 
secondary KRAS mutations in 60% of the cases. KRAS-
mutant alleles were also detectable in the blood samples 
of cetuximab-treated patients as early as 10 months before 
disease progression appeared on restaging scans. [32] In 
our study we did not perform serial plasma collections 
at multiple time points; however, we noticed several 
interesting observations. For instance, we found in patients 
with NSCLC and EGFR mutations in the tumor tissue and 
prior therapy with EGFR inhibitors, secondary mutations 
Table 4: Multivariable analysis of 105 patients with cfDNA mutations, which included mutant 
cfDNA (</= 1% vs. > 1%) and RMH score (0–1 vs. 2–3) or MDACC score (0–2 vs. 3–5)
Outcome Variable Hazard ratio 95% Confidence interval P value
Overall survival
(RMH model)
cfDNA (</= 1% vs. > 1%) 0.49 0.29–0.81 0.005
RMH score (0–1 vs. 2–3) 0.87 0.55–1.39 0.57
Overall survival
(MDACC model)
cfDNA (</= 1% vs. > 1%) 0.51 0.32–0.82 0.005
MDACC score (0–2 vs. 3–5) 0.61 0.38–0.96 0.033
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(EGFR T790M and PIK3CA E545K) in plasma cfDNA or 
KRAS or BRAF mutations in the cfDNA of patients with 
colorectal cancer with wtKRAS in tumor tissue treated 
with EGFR antibodies, credibly explaining adaptive 
resistance to therapy.
Finally, it has been suggested that the presence 
and amount of mutant cfDNA can be associated with 
progression-free and OS. [16, 28, 33, 34] For instance, 
in a pivotal study, the absence of cfDNA in patients with 
colorectal cancer after surgical resection was associated 
with 100% recurrence-free survival. [16] Similarly, a 
higher amount of cfDNA and KRAS-mutant cfDNA found 
in patients with advanced colorectal cancer treated with 
irinotecan and cetuximab and in patients with advanced 
NSCLC treated with carboplatin and vinorelbine was 
associated with a shorter progression-free survival and 
OS. [33, 34] Finally, in a group of 206 patients with 
metastatic colorectal cancer, a higher concentration of 
cfDNA negatively correlated with OS. [28] In our study, 
a higher percentage of mutant cfDNA, irrespective of 
type of the mutation, was associated with a shorter OS 
(7.4 months vs. 5.3 months; p = 0.029), which was 
confirmed in a multivariable analysis (HR 0.49, 95% CI 
0.29–0.81, p = 0.005). We made a similar observation in 
a separate analysis of patients with KRAS mutations in 
cfDNA, which comprised the largest subgroup of our total 
patient population. Nevertheless, these results need to be 
interpreted cautiously and validated in future studies since 
they might have been influenced by tumor heterogeneity, the 
heterogeneity of our studied population and other factors.
In summary, we demonstrated that molecular 
analysis of cfDNA for selected oncogenic mutations 
in BRAF, EGFR, KRAS, and PIK3CA is feasible and 
demonstrates acceptable concordance with standard of 
care mutation testing of archival tumor tissue and that the 
amount of mutant cfDNA is an independent prognostic 
factor for survival. The possible impact of cfDNA 
mutations on survival must be interpreted with caution 
because of the retrospective nature of the study and the 
absence of a validation cohort. Furthermore, other factors 
such as tumor burden and proliferative activity were 
not assessed. Finally, even if a higher mutation burden 
predicts poor survival it remains unclear whether adding 
more effective therapies targeting underlying molecular 
aberrations and the tumor microenvironment might offset 
this effect. We also showed that mutations not originally 
found in the tumor tissue could be present at a low 
frequency in cfDNA, which can plausibly contribute to 
therapeutic resistance. In order to prove clinical utility, 
mutation analysis of cfDNA will need to be tested 
in prospective clinical trials, which will also include 
therapeutic intervention with respect to cfDNA mutation 
status. In addition, most of the sensitive technologies 
applicable for cfDNA testing, including BEAMing in 
our study, use PCR-based technologies, which limits 
simultaneous detection for multiple mutations. New 
technologies with high sensitivity and broad multiplex 
capability need to be developed to advance the results of 
analysis to the clinical arena.
METHODS
Patients
Starting in October 2010, patients with advanced 
cancers previously treated with standard therapies, who 
were previously tested for BRAF and/or EGFR and/or 
KRAS and/or PIK3CA mutations in archival tumor tissue 
were enrolled in the study. Patients were required to be 
new referrals to the Department of Investigational Cancer 
Therapeutics as candidates for experimental therapies or 
potential patients had progressive disease if already treated 
with experimental therapies. The registration of patients 
in the database, tumor pathology assessment, and tumor 
mutation analysis were performed at MD Anderson. The 
study was conducted in accordance with MD Anderson 
Institutional Review Board guidelines.
Tumor tissue analyses
A total of 21 activating mutations in BRAF,  EGFR, 
KRAS and PIK3CA genes were investigated in archival 
tumor tissue obtained from routine clinical diagnostic 
and/or therapeutic procedures from primary or metastatic 
sites (Table 1). All histologies were centrally reviewed 
at MD Anderson. Mutation testing was performed in the 
CLIA–certified Molecular Diagnostic Laboratory within 
the Division of Pathology and Laboratory Medicine at 
MD Anderson. DNA was extracted from microdissected 
paraffin-embedded tumor sections and analyzed using 
a polymerase chain reaction-based DNA sequencing 
method for mutations outlined in Table 1 utilizing primers 
designed by the MD Anderson Molecular Diagnostic 
Laboratory. In January 2011, the assay was changed to 
mass spectrometric detection (Sequenom MassARRAY) 
and in March 2012, to next-generation sequencing (Ion 
Torrent, Life Technologies, Carlsbad, CA). The mutations 
identified during the initial screening were confirmed 
using a Sanger sequencing. The lower limit of detection 
is approximately 5–10% of the mutant allele frequency, 
which is influenced by clonal heterogeneity and the 
presence of normal tissue.
Plasma cfDNA analyses
Plasma samples used for cfDNA mutation 
analysis were obtained from whole blood collected in 
EDTA tubes, which was centrifuged and spun twice 
within 2 hours of collection. Isolation of cfDNA 
from plasma was carried out using the QIAamp 
DNA purification kit (Qiagen) and mutation analysis 
for a total of 21 mutations in BRAF, EGFR, KRAS, 
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and PIK3CA (Table 1) with BEAMing assays were 
conducted on each sample by Inostics GmbH as 
previously published. [16–18] Briefly, individual DNA 
molecules were attached to magnetic beads in water- 
in-oil emulsions and then subjected to compartmentalized 
PCR amplification. The mutational status of DNA bound 
to beads was determined by hybridization to fluorescent 
allele-specific probes for mutant or wild-type (wt) of the 
gene of interest, respectively. Quantification of mutant 
DNA was performed using flow cytometry. Investigators 
performing mutation analysis of cfDNA with BEAMing 
were blinded to the results of mutation analysis of the 
archival tumor samples. The lower limit of detection is 
approximately 0.02% of mutant allele frequency.
Statistical analysis
Concordance between mutation analysis of 
archival tumor tissue and mutation analysis of cfDNA 
from plasma samples was calculated using a kappa 
coefficient. Concordance analyses were carried out 
using GraphPad Software (GraphPad Software, Inc.; La 
Jolla; CA). OS was defined as the time interval from the 
study entry to the date of death or the date of last follow 
up, whichever occurred first. OS was estimated using 
the method of Kaplan and Meier and compared among 
the subgroups of patients using a log-rank test. [19] 
Cox proportional hazards regression models were fit to 
assess the association between patient characteristics 
and OS. [20] All tests were two-sided, and P-values 
less than 0.05 were considered statistically significant. 
All statistical analyses were carried out using GraphPad 
Software (GraphPad Software, Inc.; La Jolla; CA) and 
SPSS 21 computer software (SPSS Chicago, IL).
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